 |
|
|
| |
Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B and other Aligos studies
|
| |
| |
EASL 2022 June 22-26 London
MF. YUEN1, K. AGARWAL2, E. GANE3, A. JUCOV4, C. SCHWABE5, J. NIU6, J. HOU7, K. LE8, B. MASSETTO8, C. WESTLAND8, Q. ZHANG8, F. LAI8, M. VENKATRAMAN8, L. BLATT8, T. LIN8, S. CHANDA9, M. McCLURE8, J. FRY8
1. University of Hong Kong, Hong Kong; 2. Institute of Liver Studies, Kings College Hospital, United Kingdom; 3. University of Auckland, New Zealand; 4. ARENSIA Exploratory Medicine, Republican Clinical Hospital and Nicolae Testemitanu State University of Medicine and Pharmacy, Moldova; 5. New Zealand Clinical Research, New Zealand; 6. The First Hospital of Jilin University, China; 7. Nanfang Hospital of Southern Medical University, China; 8. Aligos Therapeutics, Inc., United States
|
| |
|
|
|
|
|
